MaxCyte, Inc. · NASDAQ:MXCT

MaxCyte — Investor Presentation (January 2021)

16 slides from MaxCyte's investor presentation, January 2021

  1. Slide 1: Driving the next generation of cell-based therapies

    Driving the next generation of cell-based therapies • Doug Doerfler, Chief Executive Officer • Amanda Murphy, CFA, Chief Financial Officer January 2021 • Ron Holtz, CPA, Chief Accounting Officer © 2021 MaxCyte, Inc. All Rights Reserved.

  2. Slide 2: Disclaimer

    Disclaimer The content of this document (the “Presentation”) has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (“FSMA”), as amended. Reliance on this document for the purpose of engaging in any investment activity may expose an individual

  3. Slide 3: Global partner of choice for non-viral cell engineering technology

    Global partner of choice for non-viral cell engineering technology Market-leading manufacturer of cell engineering enabling technologies based on proprietary flow electroporation (the ExPERT™ platform) • High efficiency, reproducible, scalable non-viral cell engineering system; proprietary platform

  4. Slide 4: Executive leadership with broad depth of experience

    Executive leadership with broad depth of experience Doug Doerfler Thomas M. Ross Executive Vice President, Global Sales President and Chief Executive Officer Amanda Murphy, CFA* James Brady, PhD Vice President, Technical Applications Chief Financial Officer and Customer Support Ron Holtz, CPA Steve

  5. Slide 5: The ExPERT Platform - For non-viral cell engineering

    ExPERT Instrument Portfolio The ExPERTTM Platform - For non-Viral cell engineering • Based on MaxCyte’s proprietary flow electroporation technology that has been optimized over 20+ years; covered by an extensive patent portfolio • Leverages a fundamental property of cells (the • High Performance • >

  6. Slide 6: ExPERT - A single delivery platform for cell engineering from concept to clinic

    ExPERTTM - A single delivery platform for cell engineering from concept to clinic Concept DoE Optimization Verification Phase I Pivotal Validation Approval On-Market Disposables (referred to as processing assemblies) facilitate scale up on same GMP platform o The new ExPERT platform (including instr

  7. Slide 7: MaxCyte: Strength in opportunity from two high-value life science markets

    MaxCyte: Strength in opportunity from two high-value life science markets DRUG DISCOVERY & DEVELOPMENT CELL THERAPY - CELLS AS DRUGS CELLS TO DISCOVER DRUGS Blue-chip client base includes 20 of the top 25 and all Licenses granted for 140+ cell therapy programs, 100+ of the top ten global pharma comp

  8. Slide 8: Well-positioned to capitalize on rapidly growing cell therapy market

    Well-positioned to capitalize on rapidly growing cell therapy market Key Constraints: • Viral vector availability/development costs Cell Therapy Market Growth • Continuing safety concerns Drivers: • Explosive CAR-T growth • Supply chain challenges • Rapid gene editing adoption • Patient access MaxCy

  9. Slide 9: MaxCyte solution: ExPERT platform is more than just a technology

    MaxCyte solution: ExPERT™ platform is more than just a technology Supporting our partners in achieving their goals Enables: Field Support o Accelerated path to the clinic o Reduced program risk Research & Development o Reduced unnecessary cash burn Regulatory o Faster path to key company milestones

  10. Slide 10: Value creation from clinical / commercial licenses

    Value creation from clinical / commercial licenses Cumulative Potential Pre-CML Milestones • Partners integrate MaxCyte technology to solve >$950m USD their cell engineering challenges for clinical products • Licensing deals include significant development milestones and high-value participation in

  11. Slide 11: MaxCyte-enabled cell therapy clinical trials

    MaxCyte-enabled cell therapy clinical trials GENETIC DISEASES INFECTIOUS DISEASES Sickle Cell Disease HIV Beta Thalassemia SOLID TUMORS HEME MALIGNANCIES Pancreatic Cancer Acute Myeloid Leukemia Ovarian Cancer Acute Lymphoblastic Leukemia Neuroblastoma Chronic Lymphocytic Leukemia/SLL Melanoma Pedia

  12. Slide 12: Financials

    y) MAGIK Vie ay Financials

  13. Slide 13: 2020 financial highlights and 2021 outlook

    2020 financial highlights and 2021 outlook • Robust revenue growth in full year 2020: $26.2m revenue, 21% yr/yr growth and 15% over 2H 2019 despite a challenging COVID environment • Added four additional strategic license customers in the last 12 months (3 signed in 2020 and one signed in early Janu

  14. Slide 14: Solid five-year financial results

    Solid five-year financial results 2015-2020 Revenue Instruments Placed Partnered Programs (USD, 000s) Rapid Growth of Licensed Placements Rapid Growth of Licensed Programs Total Commercial Licenses* 5 Year Revenue CAGR 23% 2020 100+ 140 + 12 2020 400 + 2020 $26,200 2019 70 + 100+ 8 2019 320 + 70 + 2

  15. Slide 15: Summary and outlook for 2021 and beyond

    Summary and outlook for 2021 and beyond 2020 Conclusions 2021 Goals 1. Reported 21% revenue growth despite a 1. Accelerate top-line growth challenging COVID environment 2. Complete manufacturing expansion/automation 2. Continued to expand capabilities in 3. Continue to launch new PAs to address cust

  16. Slide 16: Thank You

    Thank You ir@maxcyte.com www.MaxCyte.com

MaxCyte — Investor Presentation (January 2021) on 6ix